• Silo Pharma reported positive nine-month stability results for SPC-15, its investigational intranasal prophylactic for PTSD.
• Results have already been presented, supporting continued progress toward an FDA IND submission.
• Data indicates the product remained stable over the test period, reducing near-term formulation or device risk.
• The update moves the program closer to a first-in-human Phase 1 clinical trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230817PRIMZONEFULLFEED9750849) on June 23, 2026, and is solely responsible for the information contained therein.